The current drug development model for cancer treatment is criticized for its inefficiency and high costs, often resulting in minimal benefits for the majority of patients. With a staggering 95% failure rate and exorbitant annual costs averaging $100,000, many patients endure both financial and physical hardships without seeing significant improvement. The disconnect between cancer scientists and patient experiences highlights the urgent need for reform in how cancer treatments are developed and evaluated.
